54.30
-2.7(-4.74%)
Currency In GBp
Address
Thorp Arch Estate
Wetherby, LS23 7FA
United Kingdom of Great Britain and Northern Ireland
Phone
44 1904 217 070
Website
Sector
Healthcare
Industry
Biotechnology
Employees
154
First IPO Date
September 08, 2003
| Name | Title | Pay | Year Born |
| Dr. Christina Marie Coughlin B.S., M.D., Ph.D. | Chief Executive Officer, Interim Chief Medical Officer and Director | 53,000 | 1970 |
| Mr. R. Craig Slater FCA | Chief Operating Officer of Diagnostics | 69,000 | 1964 |
| Mr. Michael Vinegrad | Group Communications Director | 0 | N/A |
| Ms. Anne McGurk | Joint Managing Director of Launch Diagnostics | 0 | N/A |
| Mr. David Wilson | Chief Commercial Officer of Diagnostics | 0 | N/A |
| Dr. Simon Bennett BSc DPhil | Chief Business Officer of Therapeutics | 0 | N/A |
| Ms. Emma Wright | Group In-House Counsel | 0 | N/A |
| Mr. Brian M. Hahn | Chief Financial Officer | 0 | 1974 |
| Dr. Michelle Morrow Ph.D. | Chief Scientific Officer | 0 | N/A |
| Ms. Karen Harrison | Chief Operating Officer of Therapeutics Division | 0 | N/A |
Avacta Group Plc, a clinical stage biopharmaceutical company, develops cancer therapies and diagnostics based on its proprietary Affimer and pre|CISION platforms in the United Kingdom, North America, South Korea, and rest of Asia and Europe. It operates through Diagnostics and Therapeutics segments. The company develops custom Affimer proteins for customer products and in-house diagnostic assays. It also develops AffiDX SARS-CoV-2 lateral flow rapid antigen tests, as well as Affimer reagents for third party products; and novel cancer immunotherapies combining proprietary platforms. The company has a research collaboration with pre|CISION technology incorporates a substrate that is sensitive to cleavage by fibroblast activation protein alpha; drug development collaboration with LG Chem Life Sciences; partnership with Tufts University School of Medicine for developing Affimer drug conjugate therapies; licensing agreement with POINT Biopharma Inc. for the development of tumour activated radiopharmaceuticals; and drug development partnership with AffyXell to develop engineered mesenchymal stem cells to treat autoimmune diseases. Avacta Group Plc was incorporated in 2003 and is based in Wetherby, the United Kingdom.